Our Science

Our Approach

Innovating cancer care, by design

Immunotherapies have transformed cancer treatment, but considerable challenges remain. Many people living with cancer are not eligible for immunotherapies, and among those who are eligible, only a small portion respond well to current treatments. At Mural Oncology, we are working to increase the number of patients who can benefit from immunotherapy.

Mural employee hands studying immunotherapy with bright blue gloves using lab equipment
microscopic scan of a cancerous tumor before immunotherapy
Woman scientists wearing safety glasses
Needle syringe in a vial.

Innovative Protein Engineering

For cancer therapies

Through the application of our industry-leading protein engineering capabilities, we are working to develop first and best-in-class drugs that can benefit patients across a wide range of cancers, including difficult-to-treat tumor types where immunotherapies have not yet been effective.

White paint stroke top


Our Pipeline

We are developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available today.

Nemvaleukin Alfa - IL-2 Variant

Indication Discovery Preclinical Phase 1 Phase 2 Phase 3

Discovery Programs

Program Discovery Preclinical Phase 1 Phase 2 Phase 3

Last updated: March 2024

white paint stroke bottom

Understanding OUR

Cytokine-Based Immunotherapy Candidates

Our commitment extends to advancing a robust portfolio of programs aimed at expanding the horizons of cytokine-based immunotherapy, especially for cancers where treatment options remain limited. Use the links below to learn more about our portfolio of cytokine-based immunotherapy candidates.

Nemvaleukin alfa (Nemvaleukin) – Novel engineered IL-2

Nemvaleukin, an engineered IL-2 variant, maximizes anti-cancer potential and minimizes toxicity by activating CD8 T cells and NK cells, making it a promising candidate in cancer immunotherapy.

>> Learn More About Nemvaleukin

Tumor-Targeted Split IL-12

The split IL-12 program safely delivers IL-12's therapy by directing inactive components to the tumor site via tumor-specific antibodies, reducing systemic toxicities and promoting anti-cancer immune responses.

>> Learn More About Tumor-Targeted Split IL-12

Enhanced Efficacy IL-18

Enhanced efficacy IL-18 is an innovative variant of IL-18 engineered to evade binding with IL-18BP, thus aiming to unleash the full therapeutic potential of the IL-18 pathway for cancer treatment.

>> Learn More About IL-18